Hikma Pharmaceuticals Plc (LON:HIK) had its price target reduced by Barclays PLC from GBX 2,200 ($28.56) to GBX 1,500 ($19.47) in a report released on Friday. They currently have an overweight rating on the stock.

Several other analysts have also commented on the stock. Citigroup Inc. reiterated a neutral rating and issued a GBX 1,350 ($17.53) price target on shares of Hikma Pharmaceuticals Plc in a research report on Thursday. Goldman Sachs Group, Inc. (The) lowered shares of Hikma Pharmaceuticals Plc to a neutral rating and lowered their price target for the company from GBX 2,600 ($33.75) to GBX 1,310 ($17.01) in a research report on Tuesday, August 22nd. Morgan Stanley lowered shares of Hikma Pharmaceuticals Plc to an equal weight rating and lowered their price target for the company from GBX 1,600 ($20.77) to GBX 1,350 ($17.53) in a research report on Monday, August 21st. Jefferies Group LLC lowered their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,390 ($18.04) to GBX 1,045 ($13.57) and set a hold rating on the stock in a research report on Monday, August 21st. Finally, Numis Securities Ltd reiterated an add rating and issued a GBX 1,560 ($20.25) price target on shares of Hikma Pharmaceuticals Plc in a research report on Thursday, August 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of GBX 1,686 ($21.89).

Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1288.00 on Friday. Hikma Pharmaceuticals Plc has a one year low of GBX 1,101.00 and a one year high of GBX 2,346.00. The company’s market cap is GBX 3.09 billion. The company has a 50 day moving average price of GBX 1,345.28 and a 200 day moving average price of GBX 1,733.12.

ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/28/barclays-plc-cuts-hikma-pharmaceuticals-plc-hik-price-target-to-gbx-1500.html.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.